Bio-Rad Laboratories (BIO) Non-Current Deferred Tax Liability (2016 - 2025)
Bio-Rad Laboratories (BIO) has disclosed Non-Current Deferred Tax Liability for 17 consecutive years, with $1.1 billion as the latest value for Q4 2025.
- Quarterly Non-Current Deferred Tax Liability rose 29.51% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 29.51% year-over-year, with the annual reading at $1.1 billion for FY2025, 29.51% up from the prior year.
- Non-Current Deferred Tax Liability for Q4 2025 was $1.1 billion at Bio-Rad Laboratories, up from $872.6 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $3.6 billion in Q3 2021, with the low at $818.0 million in Q4 2024.
- Average Non-Current Deferred Tax Liability over 5 years is $1.6 billion, with a median of $1.5 billion recorded in 2022.
- The sharpest move saw Non-Current Deferred Tax Liability skyrocketed 98.61% in 2021, then plummeted 58.41% in 2022.
- Over 5 years, Non-Current Deferred Tax Liability stood at $3.1 billion in 2021, then plummeted by 42.23% to $1.8 billion in 2022, then dropped by 7.16% to $1.6 billion in 2023, then crashed by 50.24% to $818.0 million in 2024, then increased by 29.51% to $1.1 billion in 2025.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $1.1 billion, $872.6 million, and $961.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.